Effects of extended-release niacin with laropiprant in high-risk patients

New England Journal of Medicine

Volumn 371, Issue 3, 2014, Pages 203-212

  Landray, Martin J ^a   Haynes, Richard ^a   Hopewell, Jemma C ^a   Parish, Sarah ^a   Aung, Theingi ^a   Tomson, Joseph ^a   Wallendszus, Karl ^a   Craig, Martin ^a   Jiang, Lixin ^b   Collins, Rory ^a   Armitage, Jane ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b FUWAI HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLEEDING; BRAIN HEMORRHAGE; CANCER INCIDENCE; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN DISEASE; SKIN ULCER; TREATMENT OUTCOME;

AGED; ATHEROSCLEROSIS; CHOLESTEROL, LDL; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; INDOLES; INFECTION; MALE; MIDDLE AGED; MUSCULOSKELETAL DISEASES; NIACIN; RISK FACTORS; TREATMENT FAILURE;

EID: 84904252744     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1300955     Document Type: Article

References (34)

1. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
2. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302: 1993-2000.
3. Carlson LA. Nicotinic acid: the broadspectrum lipid drug: a 50th anniversary review. J Intern Med 2005;258:94-114. (Pubitemid 41025967)
4. Bays HE, Maccubbin D, Meehan AG, Kuznetsova O, Mitchel YB, Paolini JF. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients. Clin Ther 2009;31:115-22.
5. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013 November 12 (Epub ahead of print).
6. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011;217:Suppl 1:S1-S44. [Erratum, Atherosclerosis 2011;217:2.]
7. Jackevicius CA, Tu JV, Ko DT, de Leon N, Krumholz HM. Use of niacin in the United States and Canada. JAMA Intern Med 2013;173:1379-81.
8. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67. [Erratum, N Engl J Med 2012;367:189.]
9. Lai E, De Lepeleire I, Crumley TM, et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther 2007;81:849-57. (Pubitemid 46788299)
10. Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008;62:1959-70.
11. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34:1279-91.
12. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010;376:1658-69. [Erratum, Lancet 2011; 377:126.]
13. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35. (Pubitemid 40471450)
14. Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usualdose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45. [Erratum, JAMA 2005; 294:3092.] (Pubitemid 41627921)
15. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39. (Pubitemid 8018922)
16. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71. (Pubitemid 15107153)
17. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
18. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012;380: 572-80. [Erratum, Lancet 2012;380:564.]
19. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
20. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 1998;82(12A):29U-34U, 39U-41U.
21. Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc 2008; 83:470-8. (Pubitemid 351536472)
22. Shepherd JJ, Betteridge J, Van Gaal L, European Consensus Panel. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin 2005;21:665-82. (Pubitemid 40695288)
23. Fazio S, Guyton JR, Lin J, Tomassini JE, Shah A, Tershakovec AM. Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes Obes Metab 2010;12:983-93.
24. Digby JE, Martinez F, Jefferson A, et al. Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. Arterioscler Thromb Vasc Biol 2012;32:669-76.
25. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011;31:986-1000.
26. Anderson TJ, Boden WE, Desvigne-Nickens P, et al. Safety profile of extendedrelease niacin in the AIM-HIGH trial. N Engl J Med 2014;371:288-90.
27. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007;99(6A):22C-31C.
28. Nagakawa Y, Orimo H, Harasawa M. The anti-platelet effect of niceritrol in patients with arteriosclerosis and the relationship of the lipid-lowering effect to the antiplatelet effect. Thromb Res 1985;40:543-53. (Pubitemid 16177171)
29. Serebruany V, Malinin A, Aradi D, Kuliczkowski W, Norgard NB, Boden WE. The in vitro effects of niacin on platelet biomarkers in human volunteers. Thromb Haemost 2010;104:311-7.
30. Chesney CM, Elam MB, Herd JA, et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Am Heart J 2000;140:631-6.
31. Philipose S, Konya V, Lazarevic M, et al. Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation. PLoS One 2012;7(8):e40222.
32. Lai E, Schwartz JI, Dallob A, et al. Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects. Platelets 2010;21:191-8.
33. Lauring B, Dishy V, Luo WL, et al. Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. J Clin Pharmacol 2009;49:1426-35.
34. 2 receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin. Platelets 2011;22:495-503.